MDMA-Assisted Therapy for PTSD: Neuroplastic Change or Psychotherapeutic Catalyst?

MDMA-assisted psychotherapy has emerged as a promising treatment for post-traumatic stress disorder (PTSD), particularly in individuals unresponsive to conventional interventions such as SSRIs and trauma-focused cognitive behavioral therapy. As recent clinical trials report durable symptom remission, ongoing debate surrounds the mechanisms underlying its therapeutic effects. This review explores two major frameworks: a neurobiological model proposing that MDMA supports trauma reprocessing through fear extinction, memory reconsolidation, and neuroplasticity, and a relational model highlighting MDMA’s prosocial and empathogenic properties that enhance therapeutic alliance and suggestibility. Evidence from both human and rodent studies indicates that MDMA reduces amygdala reactivity, increases hippocampal connectivity, and modulates serotonergic and oxytocinergic signaling. Concurrently, clinical findings suggest that the quality of the therapeutic relationship plays a critical role in treatment outcomes. Rather than viewing these processes as mutually exclusive, we propose a synergistic model in which MDMA creates a “window of emotional safety” that allows for both neurobiological and interpersonal mechanisms to support healing. Understanding this dual-action model is essential for refining treatment protocols, improving therapist training, and guiding future research in psychedelic-assisted psychotherapy.